Molecular Docking Study of Akar Kuning (Arcangelisia flava) Secondary Metabolites as Src Inhibitor by Pratama, Mohammad Rizki Fadhil et al.
 122
Indonesian Journal of Cancer Chemoprevention, Oktober 2019
ISSN: 2088–0197
e-ISSN: 2355-8989
Molecular Docking Study of Akar Kuning (Arcangelisia 
flava) Secondary Metabolites as Src Inhibitor 
Mohammad Rizki Fadhil Pratama1*, Evi Mulyani1, Suratno2
1Department of Pharmacy, Faculty of Health Sciences, Universitas Muhammadiyah Palangkaraya. Palangka Raya, 
Indonesia
2Department of Medical Laboratory Technology, Faculty of Health Sciences, Universitas Muhammadiyah Palangkaraya. 
Palangka Raya, Indonesia
Abstract
  
 Proto-oncogene tyrosine-protein kinase Src is also known as simply Src, a tyrosine kinase 
protein which is one of the targets in various cancer therapies such as leukemia. Meanwhile, 
akar kuning (Arcangelisia flava) has gained significant attention as a medicinal plant that 
has a cytotoxic effect on various types of cancer cells. This study aims to determine the 
potential of secondary metabolites of akar kuning as Src inhibitors. Molecular docking was 
carried out using Autodock Vina 1.1.2 with 2HCK receptors, that quercetin and dasatinib 
were used as reference ligands. The docking results showed that the lowest free energy of 
binding was shown by berberine with a ΔG value of -9.0 kcal/mol, exceeded quercetin and 
dasatinib. However, the highest amino acid of the protein interacts similarly to quercetin and 
dasatinib was produced by jatrorrhizine, with 93.33% and 73.91% of similarity, respectively. 
Interestingly, berberine is the ligand with the third-highest similarity after jatrorrhizine and 
palmatine, while jatrorrhizine has the second-highest affinity after berberine. The results 
concluded that both berberine and jatrorrhizine is predicted to be used as Src inhibitors.
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INTRODUCTION
 Currently, research related to the efficacy 
of akar kuning (Arcangelisia flava) has recently 
been increasingly carried out, especially after the 
findings of high school students from Central Ka-
limantan who said that akar bajakah, one variant of 
the same genus with akar kuning could be used in 
breast cancer therapy. In contrast to akar bajakah 
which is still being investigated at the primary level, 
research related to akar kuning has been done long 
enough before and has passed several pre-clinical 
trials, one of which is to determine its efficacy as 
an anticancer (Haryanti & Widiyastuti, 2017). The 
spectrum of anticancer activity of the akar kuning 
itself is quite extensive, where the activity is shown 
against several types of cancer cells, including 
breast cancer and leukemia (Rad, et al., 2017).
 Several receptor proteins act as regulators 
in various cancer cases, such as estrogen and human 
epidermal growth factor receptor 2 (HER2) in breast 
cancer, as well as proto-oncogene tyrosine-protein 
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kinase Src (or simply Src) in leukemia (Pratama & 
Sutomo, 2018; Mahavorasirikul, et al., 2010). Src 
itself is a protein that acts as a regulator in the pro-
cess of cell proliferation, where the protein plays 
a role in the signaling process through TLR path-
ways. Src is included in tyrosine-kinase and plays 
a role in the phosphorylation of the amino acid ty-
rosine from other kinases (Ardito, et al., 2017). The 
increase in activity and the number of Src is known 
to be related to cancer progression by promoting 
other signals (Bhullar, et al., 2018). Various Src in-
hibitors, such as dasatinib and quercetin, have been 
discovered and developed in cancer therapies such 
as leukemia (Talpaz, et al., 2018).
 Akar kuning is known to have a variety of 
secondary metabolites that have anticancer activity. 
One of the most widely studied is berberine, a pro-
toalkaloid with a quaternary ammonium group that 
is known to have anticancer activity against sev-
eral types of cancer cells (Lu, et al., 2012). Several 
other secondary metabolites of akar kuning are also 
known to have an anticancer activity such as jat-
rorrhizine and palmatine (Qiu, et al., 2018; Long, 
et al., 2019). Previous research has shown that sec-
ondary metabolites have potential as inhibitors in 
various cancer receptors such as epidermal growth 
factor receptor (EGFR) and HER2 with quite pos-
sible results (Pratama, 2016; Pratama & Pratomo, 
2017). Considering the similarity of EGFR protein 
structure with Src as a fellow tyrosine kinase that 
plays a role in cell proliferation signaling, it is prob-
able that secondary metabolites from akar kuning 
can also be inhibitors of Src protein (Wee & Wang, 
2017). This study aims to determine the potential of 
secondary metabolites of akar kuning as Src inhib-
itors. The method used is molecular docking with a 
targeted-docking approach compared to known Src 
inhibitors such as quercetin and dasatinib.
METHODS
 The hardware used was the ASUS 
A46CB series Ultrabook with an Intel™ Core i5-
3337U@1.8 GHz and Windows 7 Ultimate 64-bit 
SP-1 operating system. The software used was Hy-
perChem 8.0.8 from Hypercube Inc., OpenBabel 
2.4.1 from OpenBabel.org., AutoDockTools 1.5.6 
and Autodock Vina 1.1.2 software from The Scripps 
Research Institute Inc., PyMOL 2.3.1 from Schrod-
inger LLC., UCSF Chimera 1.13.1 from University 
of California, San Francisco, and Discovery Studio 
Visualizer 19.1.0 from Dassault Systems Biovia 
(Trott & Olson, 2010; O’Boyle, et al., 2011; Yuan, 
et al., 2017; Pettersen, et al., 2004). Information on 
three-dimensional structures of receptor proteins 
obtained from the website of Protein Data Banks 
(http://rcsb.org).
 The test ligand used were 11 secondary 
metabolites of akar kuning as shown in Figure 
1 consisting of 2-dehydroaxyarcangelisinol (1), 
6-hydroxyarcangelisin (2), 6-hydroxyfibleucin (3), 
6-hydroxyfibraurin (4), berberine (5), columbamine 
(6), fibleucin (7), fibraurin (8), jatrorrhizine (9), pal-
matine (10), and tinophyllol (11) (Pratama, et al., 
2018; Ginovyan, et al., 2017; Yi, et al., 2018). Also 
used is the reference ligand, dasatinib, a small-mol-
ecule tyrosine kinase inhibitor that has been used 
and is marketed as an Src inhibitor in the treatment 
of leukemia. The two-dimension structure of all test 
ligands was drawn using HyperChem 8.0.8. Ideal 
conformation of all test ligands has been provided 
by performing energy minimization by ab initio 
method basis set 3-21G, which approaching ideal 
conformation of these compounds in nature (Fer-
reira, et al., 2015). Optimized structures format 
changed from.log to.pdb using Open Babel 2.4.1. 
In this study, Autodock Vina 1.1.2 was used as a 
Docking program. The accuracy and speed of the 
calculation process are the main advantages of the 
docking process with Autodock Vina, where the 
disadvantages are that it requires other software to 
interpret the results (Pagadala, et al., 2017). For the 
observation of docking results in two dimensions 
using Discovery Studio Visualizer 19.1.0. The ad-
vantage of the software is that the type of amino 
acid interactions that occur can be observed in de-
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tail. All ligands then are given the charge and set 
torque by default using software AutoDockTools 
1.5.6 (Forli, 2015).
 The molecular structure of Src receptor was 
obtained from the website of Protein Data Bank 
(PDB) http://www.rscb.org with PDB ID 2HCK. 
The receptor is in the form of a dimer with a resolu-
tion of 3 Å bind to a reference ligand of quercetin, a 
flavonoid that is known to have a variety of pharma-
cological activities, one of which is as an antican-
cer (Sicheri, et al., 1997). The receptor was down-
loaded in.pdb format and then removed the unused 
portion, added the non-polar hydrogen group, given 
the charge, and set the grid box size as well as co-
ordinate using software AutoDockTools 1.5.6. The 
grid box size was obtained through the orientation 
process until the smallest grid box was obtained 
with an root-mean-square deviation (RMSD) value 
below 2 Å. The used chain-domain of the receptor 
is the active site which is bind to Src inhibitor, in 
this case, quercetin (Morris, et al., 2009; Ramirez 
& Caballero, 2018).
 The validation process was carried out by 
the re-docking method, where the quercetin from the 
2HCK receptor was extracted, added the non-polar 
hydrogen group, given the charge, torque and rota-
tional bond was adjusted, then saved in the .pdbqt 
format. The reference ligand was then re-docked at 
the grid box position and size predetermined from 
the orientation result (Megantara, et al., 2016). The 
parameters observed in the validation process are 
RMSD of reference ligand at the selected binding 
site. The RMSD score illustrates the average differ-
ence in ligand atom position redocking with crys-
tallographic results, while the smaller the RMSD 
value indicates the accuracy of the docking results 
that approaching the results of crystallography. 
The maximum value of RMSD which is often the 
benchmark for the docking validation process is 2 
Å, where the RMSD value less than 2 Å indicating 
a valid docking result (Castro-Alvarez, et al., 2017; 
Pagadala, et al., 2017).
 The primary objective of the molecular 
docking is to identify the energetically favorable 
binding modes or binding pose of test ligands into 
the target receptor’s selected binding site (Atk-
ovska, et al., 2014). Docking for all test ligands 
performed in the same way as the validation pro-
cess with similar size and position of the grid box. 
The main parameter used in docking process with 
Autodock Vina was the free energy of binding (ΔG) 
as affinity marker and amino acids residues as in-
teraction marker (Forli, et al., 2016; Natesan, et 
al., 2012). The more negative ΔG shows the higher 
ligand affinity for the selected binding site of the 
receptor. The amino acids residues of all test lig-
and then compared with reference ligand to assess 
the similarity of interaction between test and refer-
ence ligand. The more similar amino acid residues 
indicate a higher probability that the test ligand will 
have a similar type of interaction with the reference 
ligand (Pratama, et al., 2018; Singh, et al., 2016).
Figure 1. Structure of known secondary metabolites from akar kuning (Pratama, et al., 2018)
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RESULTS
 Redocking results from this study were 
provided RMSD score of 1.210 Å, indicated that 
the receptor 2HCK used was valid for docking 
purpose. Visualization of ligand overlays result-
ing from redocking with co-crystal ligands from 
crystallographic results is presented in Figure 2. 
Other parameters observed in the validation pro-
cess are ΔG and amino acid residues, including 
size and grid box coordinates, as shown in Table 1.
 The docking of the eleven test ligands and 
dasatinib showed exciting results that several test 
ligands have an affinity that is comparable to the 
dasatinib or quercetin as ligand references. Ber-
berine, columbamine, jatrorrhizine, and palmatine 
showed ΔG, which is comparable or more negative 
than quercetin, where berberine even has a more 
negative ΔG value than dasatinib, as presented in 
Table 2. Practically, these results indicate that ber-
berine has the potential to compete with both dasat-
inib and quercetin as inhibitors at Src binding sites. 
However, the ΔG value of berberine with dasatinib 
itself only has a difference of 0.1 kcal/mol, each 
worth -9.0 kcal/mol and -8.9 kcal/mol, respectively. 
On the other hand, jatrorrhizine has the next most 
negative ΔG value with a value of -8.8 kcal/mol, 
again only having a 0.1 kcal/mol difference with 
dasatinib. At a glance, it can be concluded that both 
berberine and jatrorrhizine have the free energy of 
binding that is similar at the binding site of Src.
 Observations of amino acid residues show 
exciting results, as presented in Tables 3. Dasat-
inib, which is already known to have acted as an 
Src inhibitor, has 100% amino acid residues similar 
to quercetin, where the similarity to the type of in-
teraction that also occurs quite high at 60%. While 
from the test ligands, the highest similarity was 
shown by jatrorrhizine, with 93.33% similar amino 
acid residues and 53.33% similar types of interac-
tions compared to quercetin. However, berberine it-
self  also shows a reasonably high similarity to both 
quercetin  and dasatinib. Besides, both  jatrorrhiz-
ine and berberine  have   relatively  similar binding 
motives, as can  be  seen  visually  in Figure 3 and 
Figure 4.
Figure 2. Overlays of redocking (blue) ligands with co-crystal ligands from crystallography (green) at 2HCK 
receptor; RMSD= 1.210 Å
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Figure 3. Interactions of berberine in amino acid 
residues from 2HCK receptors
Figure 4. Interactions of jatrorrhizine in amino acid 
residues from 2HCK receptors
Table 1. Results of the validation process of 2HCK receptor
*Alkyl/Pi-alkyl interaction; **Van der Waals interaction; 
***Pi-sigma interaction; ****Hydrogen bond
Parameters Value 
PDB ID 2HCK 
Reference ligand Quercetin 
Grid box size (Å) 40 x 30 x 30 
Grid box position 
x: 30.556 
y: 45.903 
z: 99.090 
RMSD (Å) 1.21 
 -8.5 
Amino acid residues 
273-Leu* 
274-Gly** 
281-Val*** 
293-Ala* 
323-Val** 
338-Thr** 
339-Glu**** 
340-Phe** 
341-Met** 
344-Gly**** 
345-Ser**** 
390-Ala** 
393-Leu*** 
403-Ala* 
404-Asp** 
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Table 2. Results of the docking process of test ligands at binding site of 2HCK receptor
Das: dasatinib; *Alkyl/Pi-alkyl interaction; **Van der Waals interaction; ***Pi-sigma interaction; ****Hydro-
gen bond; *****Pi-cation/anion; ******Unfavorable bump/donor-donor
Ligand Das 1 2 3 4 5 6 7 8 9 10 11 
(kcal/mol) -8.9 -7.8 -7.4 -7.4 -8.2 -9.0 -8.5 -7.9 -7.5 -8.8 -8.5 -7.2 
Amino 
acid 
residues 
- 117-Glu***** 
117-
Glu***** 
117-
Glu** - - - 
117-
Glu** 
117-
Glu** - - 
117-
Glu** 
- - - 118-Trp** - - - - - - - - 
- - 135-Asn** - - - - - - - - 
135-
Asn** 
- - - - 161-Gln** - - - - - - - 
- - - - 248-Ser** - - - - - - - 
- - - - - - - - - - - 250-Pro** 
- - 251-Gln** - 
251-
Gln**** - - - - - - 
251-
Gln** 
- - 253-Pro**** - - - - - - - - 
253-
Pro** 
- 254-Trp* 
254-
Trp** 
254-
Trp**** - - - 
254-
Pro* 
254-
Pro** - - 
254-
Pro** 
- - - 255-Glu** - - - 
255-
Glu** 
255-
Glu** - - - 
- - - 257-Lys** - - - - 
257-
Lys** - - - 
- - - 258-Asp****** - - - 
258-
Asp**** 
258-
Asp**** - - - 
- - - 259-Ala** - - - - 
259-
Ala** - - - 
- 260-Trp** - 
260-
Trp** - - - 
260-
Trp** 
260-
Trp* - - - 
273-
Leu* - - - - 
273-
Leu** 
273-
Leu** - - 
273-
Leu* 
273-
Leu* - 
274-
Gly** - - - - - - - - 
274-
Gly** - - 
- - - - - - - - - 275-Ala**** - - 
276-
Gly** - - - - 
276-
Gly** 
276-
Gly** - - 
276-
Gly** 
276-
Gly** - 
277-
Gln** - - - - 
277-
Gln** 
277-
Gln** - - - - - 
281-
Val* - - - - 
281-
Val*** 
281-
Val*** - - 
281-
Val* 
281-
Val*** - 
293-
Ala* - - - - 
293-
Ala** 
293-
Ala** - - 
293-
Ala* 
293-
Ala** - 
295-
Lys** - - - - 
295-
Lys**** 
295-
Lys**** - - 
295-
Lys** 
295-
Lys** - 
- 315-Lys**** - 
315-
Lys* - - - 
315-
Lys* 
315-
Lys* - - - 
- - - 316-His** - - - - - - - - 
- 318-Gln** 
318-
Gln** 
318-
Gln**** - - - 
318-
Gln**** 
318-
Gln** - - 
318-
Gln** 
- - 319-His** - - - - - - - - 
319-
His** 
- - 320-Asp** - 
320-
Asp** - - - - - - 
320-
Asp** 
- - - - 321-Lys** - - - - - - - 
323-
Val** - - - - - - - - 
323-
Val** - - 
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DISCUSSION
 The docking protocol is done by using en-
ergy range 3, exhaustiveness 18, and the number of 
modes 9. In addition to exhaustiveness, values for 
other parameters were the default values of Auto-
dock Vina. The value of exhaustiveness is increased 
from 8 to 18 to increase the robustness of the dock-
ing performed (Forli, et al., 2016). Molecular dock-
ing was performed using configuration settings 
similar to the validation process with changes to 
the test ligand file used (Ravindranath, et al., 2015). 
One interesting finding is that of all the test ligands 
used, the four that have an affinity value that can be 
compared with quercetin are berberine, columbam-
ine, jatrorrhizine, and palmatine. The four ligands 
have structural similarities to the benzylisoquino-
line parent group with different variations of the 
hydroxy and methoxy groups in substituents num-
ber 2, 3, 9, and 10. Whereas specifically for ber-
berine, it is replaced with 1,3-benzodioxole groups 
(Khan & Kumar, 2015). In addition to the structural 
similarities, the four compounds are also known to 
have anticancer activity, one of which is quite well 
known is berberine. Berberine has even been mar-
keted in oral dosage forms such as capsules and is 
used in various types of therapies such as diabetes, 
dyslipidemia, and as vitamins, although no prepa-
rations have been produced with indications as an-
ticancer (Neag, et al., 2018). The development of 
berberine derivatives itself is still underway, one of 
which is by making derivatives with more potent 
anticancer activities (Pratama & Pratomo, 2017).
While from the test ligands, the highest similarity 
was shown by jatrorrhizine, with 93.33% similar 
amino acid residues and 53.33% similar types of 
interactions compared to quercetin. In addition, 
jatrorrhizine also showed a very high similarity to 
dasatinib with 73.91% similarity of amino acid resi-
dues and 56.52% similarity of interaction types. The 
berberine ranks only third with the highest similar-
ity for quercetin and dasatinib. The high amino acid 
residue similarity and interaction of jatrorrhizine 
increases the probability that jatrorrhizine will have 
activity as an Src inhibitor with a mechanism of ac-
tion similar to quercetin and dasatinib. Moreover, 
the value of ΔG jatrorrhizine itself is higher than 
Quercetin and only 0.1 kcal/mol adrift of dasatinib. 
One of the causes of the high similarity is that jat-
rorrhizine interacts with a lot of amino acids which 
are 18 in number, most compared to other test lig-
ands. The more significant number of interactions 
of amino acid residues will undoubtedly increase 
the probability of similarity in types of interactions, 
while also potentially increasing ligand affinity 
(Araujo & Logothetis, 2010; Luscombe, et al., 2001).
The main difference in the interactions between 
berberine and jatrorrhizine is due to the orientation 
of the benzodioxole group of berberine at different 
binding sites with the methoxy and hydroxyl groups 
of jatrorrhizine. The methoxy group itself has 
higher torque so it can move more freely than the 
more rigid benzodioxole group. Hence more amino 
acid residues can interact (Gupta, et al., 2009). 
However, even though Jatrorrhizine has more inter-
actions than berberine, berberine still has a higher 
affinity, which indicates that the interactions of the 
benzodioxole group are relatively stronger (Papi, 
et al., 2017). It is interesting to observe whether 
berberine will also produce interactions similar to 
jatrorrhizine, considering the similarity levels of 
amino acid residues with both quercetin and dasat-
inib are also relatively high. Therefore, a combina-
tion of berberine and jatrorrhizine has the potential 
to be used to obtain optimal Src inhibitory activity.
CONCLUSION
 This study successfully demonstrated that 
among the secondary metabolites of other akar 
kuning, the highest potential for Src inhibitors 
was demonstrated by berberine and jatrorrhizine. 
While berberine shows higher affinity compared 
to reference compounds such as quercetin and da-
satinib, jatrorrhizine shows very high amino acid 
interaction similarities with the reference ligand. 
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The combination of both is expected to optimize 
the activity of the resulting Src inhibitors. Fur-
thermore, further in vitro research including toxic-
ity assay can be carried out to prove the potential 
of the combination of the two as Src inhibitors. 
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